Form 10Q/A
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                   Quarterly Report Under Section 13 or 15 (d)
                     of the Securities Exchange Act of 1934

For Quarter Ended:          Feb. 28, 2003
                  -----------------------------------------------
Commission File Number:      0-11050
                       ------------------------------------------

                              Mammatech Corporation
              ----------------------------------------------------
             (Exact name of registrant as specified in its charter)

           Florida                                             59-2181303
 ------------------------------                            -------------------
(State or other jurisdiction of                           (I.R.S. Employer
 incorporation or organization)                           Identification Number)


930 N.W. 8th Avenue, Gainesville, Florida                        32601
 --------------------------------------                         --------
(Address of principal executive offices)                       (Zip Code)


                                 (352) 375-0607
               --------------------------------------------------
              (Registrant's telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past ninety days. Yes  X  No
                                          -----  -----

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date:

                                              Number of shares outstanding on
                                                        Feb. 28, 2003
                                                        -------------
                                              100,458,333 shares of which
                                              7,408,500 are treasury shares
TITLE OF EACH CLASS
-------------------
Common stock $.0001 par value


The total number of pages of this report is 11.

                                       1

<PAGE>


                              Mammatech Corporation




                                      INDEX
        -----------------------------------------------------------------

                                     PART I.

              FINANCIAL INFORMATION                                    PAGE NO.


                          Item 1. Financial Statements

                    Statements of Operations for Three Months
           Ended Feb. 28, 2003 and Feb. 29, 2002..........................3

                    Balance Sheets for Feb. 29, 2003 and
           August 31, 2002..............................................4-5

                    Statement of Cash Flow for the Six Months
           Ended Feb. 28, 2003............................................6

                    Statement of Cash Flow for the Six Months
           Ended Feb. 29, 2002............................................7

                    Notes to Financial Statements for the Quarter
           Ended Feb. 28, 2003............................................8


           Item 2. Management's Discussion and Analysis of
           Financial Conditions and Results of Operations.................9


                           PART II. OTHER INFORMATION


           Item 6. Exhibits and Reports on Form 8-K......................10

              SIGNATURES.................................................11

                                       2

<PAGE>
<TABLE>
<CAPTION>


                                    Mammatech Corporation
                            Statements of Comprehensive Operation
                                         (Unaudited)


                                  Six Months Ended                Three Months Ended
                                  ----------------                ------------------
                              February         February         February         February
                                2003             2002             2003             2002
                           -------------    -------------    -------------    -------------
<S>                        <C>              <C>              <C>              <C>
Sales, net                 $     256,325    $     153,499    $     118,167    $      84,999

Cost of sales                     55,684           41,484           29,483           20,324

Gross Profit                     200,641          112,015           88,684           64,675

Selling, General and             191,763          180,767           95,431           86,554
Administrative Expenses
Operating gain (loss)              8,878          (68,752)          (6,747)         (21,879)

Other Income (SBIR)               46,254              -0-           21,115              -0-
Other Income                       2,400            2,400
Interest and dividends            14,145           14,224            6,565            6,152

Pre-tax income                    69,277          (52,128)          20,933          (13,327)


Provision for income tax         (11,355)             -0-           (3,140)             -0-


Comprehensive Income              57,922          (52,128)          17,793          (13,327)
(loss)
Comprehensive Income                 .00              .00              .00              .00
(loss) per share
Weighted average shares      100,462,500      100,462,500      100,462,500      100,462,500
                           =============    =============    =============    =============


                           The accompanying notes are an integral
                              part of the financial statements.

                                              3
</TABLE>

<PAGE>


                              Mammatech Corporation
                                 Balance Sheets


                                                  Feb. 28, 2003    Aug. 31, 2002
                                                   (Unaudited)       (Audited)
                                                    ---------         -------
ASSETS
------

  Cash and Cash Equivalents                        $  581,270       $  503,556
   Marketable securities                              269,129          269,129

  Accounts receivable:
    Trade                                              61,565           54,434
    Other                                                 -0-              -0-
  Inventory                                            56,625           78,446
  Other current assets
     Deferred tax asset-
         current portion                               11,355            5,100

  Total Current Assets                                979,944          910,665

Property and equipment                                 28,840           24,651

Other assets:
  Deferred tax asset-
   Non current portion                                155,635          159,680


  Patents, trademarks, and
  other intangibles, net of
  accumulated amortization
  of $53,080 and $46,942
  respectively                                         11,914           17,724


Total other assets                                    196,389          202,055
                                                   ----------       ----------

TOTAL ASSETS                                       $1,176.333       $1,112,720
                                                   ==========       ==========


                     The accompanying notes are an integral
                       part of the financial statements.

                                        4

<PAGE>


                              Mammatech Corporation
                                 Balance Sheets

                              As of August 31, 2002
                                and Feb. 28, 2003
                                   (continued)

                                                      Feb. 2003      Aug. 2002
                                                     -----------    -----------

LIABILITIES AND STOCKHOLDERS' EQUITY
------------------------------------

CURRENT LIABILITIES
-------------------
Current portion of long term debt                    $     6,260    $     6,260
Accounts payable-trade                                    10,191         16,598
Accrued payable-officer                                    6,630          6,630
Accrued salaries                                         540,033        541,495
Accrued royalties                                         79,705         79,705
                                                                    -----------


TOTAL CURRENT LIABILITIES                                642,819        650,688
                                                     -----------    -----------


COMMITMENTS

Stockholders' equity:

  Common stock, par value $.0001;
  200,000,000 shares authorized;
  100,352,500 shares issued
  and outstanding                                    $    10,046    $    10,046

  Additional paid-in capital                           2,811,183      2,811,183
  Accumulated deficit                                 (2,013,761)    (2,085.243)
                                                     -----------    -----------
                                                         807,468        735,986
  Valuation allowance for
  marketable securities                                 (125,903)      (125,903)

  Treasury stock at cost,
  6,208,500 shares                                      (148,051)      (148,051)
                                                     -----------    -----------
                                                         533,514        462,032
                                                     -----------    -----------

TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY                                 $ 1,176,333    $ 1,112,720
                                                     ===========    ===========


                     The accompanying notes are an integral
                            part of these statements.

                                        5

<PAGE>


                              Mammatech Corporation
                             Statement of Cash Flow
                            For the Six Months Ending
                                  Feb. 28, 2003


Net income (loss)                                                     $  69,277

Adjustments to reconcile net income
    (loss) to net cash provided by
    operating activities:

  Depreciation and amortization                                           6,000

  Common stock issued for services                                         --

Changes in assets and liabilities:

    (Increase) decrease in accounts receivable (7,131)

    (Increase) decrease in available for sale securities                   --

    (Increase) decrease in inventory                                     21,821
    (Increase) decrease in other assets                                  (1,008)
    (Increase) decrease in deferred tax asset

    Increase (decrease) in accounts payable                              (6,407)

    Increase (decrease) in accrued expenses                              (1,462)

       Total adjustments                                                 11,813
                                                                      ---------

  Net cash provided by
   operating activities                                                  81,090
                                                                      ---------

Cash flows from investing activities:

   Acquisition of property and equipment                                   (939)
                                                                      ---------
   Net cash (used in) investing activities                                 (939)
                                                                      ---------

Cash flows from financing activities:

   Repayment of note payable

 Net cash (used in)
   financing activities

Increase (decrease) in cash                                              80,151
Cash and cash equivalents,

 beginning of period                                                    503,556
                                                                      ---------

Cash and cash equivalents, end of period                              $ 583,707

See accompanying notes to financial statements.


                     The accompanying notes are an integral
                        part of the financial statements.

                                        6

<PAGE>


                              Mammatech Corporation
                             Statement of Cash Flow
                            For the Six Months Ending
                                  Feb. 28, 2002



Net income (loss)                                                     ($ 52,128)

Adjustments to reconcile net income
 (loss) to net cash provided by operating
 activities:

   Depreciation and amortization                                          7,500

   Common stock issued for services                                        --

Changes in assets and liabilities:

    (Increase) decrease in accounts receivable 88,280

    (Increase) decrease in available for sale securities                   --

    (Increase) decrease in inventory                                     16,983
    (Increase) decrease in other assets                                  (2,075)
    (Increase) decrease in deferred tax asset
                                                                         (2,210)
    Increase (decrease) in accounts payable                             (23,160)

    Increase (decrease) in accrued expenses                             (10,921)

       Total adjustments                                                 74,397
                                                                      ---------

  Net cash provided by operating activities                              22,269
                                                                      ---------

Cash flows from investing activities:
   Acquisition of property and equipment                                 (3,008)
                                                                      ---------
   Net cash (used in) investing activities                                  -0-

Cash flows from financing activities:
   Repayment of note payable                                                -0-
  Net cash (used in)                                                        -0-
   financing activities

Increase (decrease) in cash                                              19,261

Cash and cash equivalents,
    beginning of period                                                 578,054
                                                                      ---------

Cash and cash equivalents, end of period                              $ 597,315

See accompanying notes to financial statements.

                                        7

<PAGE>


                              Mammatech Corporation
                          Notes to Financial Statements
                                  Feb. 28, 2003


Note 1.   In the opinion of the Company, the accompanying unaudited financial
          statements contain all adjustments (consisting of only normal
          recurring accruals) necessary to present fairly the financial position
          as of Feb. 28, 2003, and the results of operations and changes in
          financial on for the three months ended Feb. 28, 2003.

Note 2.   Earnings (loss) per share is based on the weighted average number of
          shares outstanding during each period.

Note 3.   Expenditures associated with activities supported by federal research
          grants are reimbursed and appear as other income.

                                        8

<PAGE>


                MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
          CONDITIONS AND RESULTS OF OPERATION FOR MAMMATECH CORPORATION

The results of the second quarter of Fiscal 2003 are mixed in comparison to the
previous quarter and the second quarter of 2002. The six-month data show uniform
improvement, however. Quarterly sales revenues increased by 39% from the same
period a year ago but declined by 14.5% in comparison to the previous quarter.
Similarly, gross profit increased by 37% compared to the second quarter of 2002
but was 20.7% less than the figure for last quarter. Operating expense during
the current quarter relative to the first quarter decreased by 1.1% but was 10%
higher than in the second quarter of 2002. The resulting net income of $17,792
compares favorably to a loss of $13,327 during the same quarter last year but is
down by 57% in comparison to the prior quarter of the fiscal year.

A more encouraging picture emerged with respect to the six-month figures. Sales
revenues increased by 67% coupled with an operating expense increased of only 6%
compared to the first six months of 2002. The net income for the first half of
the year increased $110,050 from a net loss in the same period a year ago.

The decline in sales relative to the previous quarter reflects the general
economic malaise in the national economy in combination with insufficient
inventory to service some large orders from customers in Germany and France. A
portion of these revenues will be recognized in the third quarter and the
company has increased production to meet future demands of this kind.

The Company trained 12 MammaCare Specialists during the quarter, down from 17
trained during the second quarter of 2002 but up from 3 the previous quarter. An
increasing number of these specialists are being trained in the University of
Florida College of Nursing facility under the agreement executed in the first
quarter. In addition, the Company introduced a new one-day training program in
clinical breast examination. The second individual to complete this program and
receive certification is a widely recognized health professional at the National
Institutes of Health. His evaluation of the program was laudatory. The Company
has launched a targeted marketing program on behalf of the new clinical breast
examination training procedure but there can be no assurance that any
substantial revenues will result.

The Company is continuing its efforts to develop MammaCare Training Centers in
medical and nursing schools. Negotiations have begun with a major medical
institution on the west coast for an agreement to be consummated by early summer
but there is no assurance an agreement will be finalized.

The Company remains essentially debt free and has no immediate liquidity
problems. In the light of the present earnings picture, management sees no need
to adjust the value of the deferred tax asset. The Company continues to seek
other opportunities to expand its marketing and manufacturing activities to meet
the growing world-wide interest in its products.

                                        9

<PAGE>


PART II - OTHER INFORMATION


Item 6.    Exhibits and Reports on Form 8-K

   (a.)    Exhibits

           99.1 Certification of CEO Pursuant to Section 906 of the
                Sarbanes-Oxley Act 0f 2002.

           99.2 Certification of CFO Pursuant to Section 906 of the
                Sarbanes-Oxley Act 0f 2002.

   (b.)    There were no reports filed on Form 8-K during the three months
           ending Feb. 28, 2003.

                                       10

<PAGE>


                                      10-Q/A

                    For the three months ended Feb. 28, 2003
                                   Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.





                                            MAMMATECH CORPORATION
                                            =====================




DATE: May 14, 2003                        BY:  /s/  Henry S. Pennypacker
                                               --------------------------------
                                                      Henry S. Pennypacker,
                                                      President and Director


                                            BY:  /s/  Mary Sellers
                                               --------------------------------
                                                      Mary Sellers, Treasurer
                                                      and Chief Financial
                                                      Officer

                                       11

<PAGE>


CERTIFICATIONS

Certification Pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act
of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Henry S. Pennypacker, Chief Executive Officer of Mammatech Corporation
certify that:


1.   I have reviewed this quarterly report on Form 10-Q/A of The Mammatech
     Corporation, ;

2.   Based on my knowledge, this quarterly report does not contain any untrue
     statement of a material fact or omit to state a material fact necessary to
     make the statements made, in light of the circumstances under which such
     statements were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my knowledge, the financial statements, and other financial
     information included in this quarterly report, fairly present in all
     material respects the financial condition, results of operations and cash
     flows of the registrant as of, and for, the periods presented in this
     quarterly report;

4.   The registrant's other certifying officer and I are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

     a.   designed such disclosure controls and procedures to ensure that
          material information relating to the registrant, including its
          consolidated subsidiaries, is made known to us by others within those
          entities, particularly during the period in which this quarterly
          report is being prepared;

     b.   evaluated the effectiveness of the registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     c.   presented in this quarterly report our conclusions about the
          effectiveness of the disclosure controls and procedures based on our
          evaluation as of the Evaluation Date;

5.   The registrant's other certifying officer and I have disclosed, based on
     our most recent evaluation, to the registrant's auditors and the audit
     committee of registrant's board of directors (or persons performing the
     equivalent functions):

     a.   all significant deficiencies in the design or operation of internal
          controls which could adversely affect the registrant's ability to
          record, process, summarize and report financial data and have
          identified for the registrant's auditors any material weaknesses in
          internal controls; and

     b.   any fraud, whether or not material, that involves management or other
          employees who have a significant role in the registrant's internal
          controls; and

6.   The registrant's other certifying officer and I have indicated in this
     quarterly report whether there were significant changes in internal
     controls or in other factors that could significantly affect internal
     controls subsequent to the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.

Date:  May 14, 2003
                                            /s/  Henry S. Pennypacker
                                            ----------------------------------
                                                 Henry S. Pennypacker, Chairman,
                                                 Chief Executive Officer and
                                                 President

                                       12

<PAGE>


Certification Pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act
of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Mary B. Sellers, Chief Financial Officer of The Mammatech Corporation,
certify that:

1.   I have reviewed this quarterly report on Form 10-Q/A of The Mammatech
     Corporation;


2.   Based on my knowledge, this quarterly report does not contain any untrue
     statement of a material fact or omit to state a material fact necessary to
     make the statements made, in light of the circumstances under which such
     statements were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my knowledge, the financial statements, and other financial
     information included in this quarterly report, fairly present in all
     material respects the financial condition, results of operations and cash
     flows of the registrant as of, and for, the periods presented in this
     quarterly report;

4.   The registrant's other certifying officer and I are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

     a.   designed such disclosure controls and procedures to ensure that
          material information relating to the registrant, including its
          consolidated subsidiaries, is made known to us by others within those
          entities, particularly during the period in which this quarterly
          report is being prepared;

     b.   evaluated the effectiveness of the registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     c.   presented in this quarterly report our conclusions about the
          effectiveness of the disclosure controls and procedures based on our
          evaluation as of the Evaluation Date;

5.   The registrant's other certifying officer and I have disclosed, based on
     our most recent evaluation, to the registrant's auditors and the audit
     committee of registrant's board of directors (or persons performing the
     equivalent functions):

     a.   all significant deficiencies in the design or operation of internal
          controls which could adversely affect the registrant's ability to
          record, process, summarize and report financial data and have
          identified for the registrant's auditors any material weaknesses in
          internal controls; and

     b.   any fraud, whether or not material, that involves management or other
          employees who have a significant role in the registrant's internal
          controls; and

6.   The registrant's other certifying officer and I have indicated in this
     quarterly report whether there were significant changes in internal
     controls or in other factors that could significantly affect internal
     controls subsequent to the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.

Date: May 14, 2003
                                            /s/  Mary B. Sellers
                                            ----------------------------------
                                                 Mary B. Sellers,
                                                 Chief Financial Officer

                                       13